Skip to content
drillr.ai
Sign up

GCTK

GlucoTrack, Inc.

NASDAQ · Healthcare · Medical - Instruments & Supplies · IL

$2.98
−10.24%
Ask drillr

  • Aug 10, 2026, 00:00 UTC

    Glucotrack, Inc. amended its 2026 equity line of credit common stock purchase agreement with White Lion Capital, LLC, setting the issuance of 2,505,513 Commitment Shares and adding a true-up payment mechanism, in connection with a $1,000,000 commitment fee.

  • Aug 5, 2026, 12:30 UTC

    Glucotrack announced approximately $5.5 million in financing, including a $2.0 million equity offering priced at $0.75 per unit and a $3.5 million convertible debt investment from institutional investors.

    Source:

  • Jul 31, 2026, 12:00 UTC

    Glucotrack, through its subsidiary Lōkahi Therapeutics, announced the continued expansion of its ai² Futures Lab, which in its first year identified over 45 therapeutic opportunities on a budget of about $33,000 and advanced five into active discussions.

    Source:

  • Jul 27, 2026, 00:00 UTC

    Glucotrack, Inc. signed an exchange agreement on July 22, 2026, to exchange a $900,000 partitioned promissory note for shares of its common stock, subject to approval by its bridge investors.

  • Jul 17, 2026, 17:20 UTC

    E.F. Hutton & Co. served as exclusive financial advisor on the strategic business combination between Glucotrack, Inc. and Lōkahi Therapeutics.

    Source:

  • Jul 17, 2026, 17:20 UTC

    E.F. Hutton & Co. served as exclusive placement agent for a convertible note financing of approximately $5.7 million to support the combined company's post-closing growth.

    Source:

  • Jul 17, 2026, 12:05 UTC

    Glucotrack, Inc. completed a bridge financing to support its strategic growth objectives following its business combination with Lōkahi Therapeutics.

    Source:

  • Jul 14, 2026, 21:40 UTC

    Glucotrack and Lōkahi Therapeutics completed a strategic business combination, establishing a Lōkahi-controlled public platform.

    Source: